PRECISION BIOSCIENCES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PRECISION BIOSCIENCES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $1.07B | Mar 10, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.26M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $68.70M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $48.73M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $25.10M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $115.53M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $24.29M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $22.24M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $10.88M | Mar 10, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($45.72M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $7.17M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($61.32M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($111.64M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($30.60M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($109.01M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($92.88M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($46.04M) | Mar 10, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($52.15M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($26.16M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($43.74M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($62.31M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($39.38M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($109.83M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($87.20M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($47.91M) | Mar 10, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.17M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $59.56M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $53.38M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $46.12M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $115.24M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $98.06M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $82.42M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $45.12M | Mar 10, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($65.84M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($58.45M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($84.11M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($45.75M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($10.85M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($87.39M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($71.02M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($51.72M) | Mar 10, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $154.42M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $136.39M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $159.78M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $238.17M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $211.50M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $150.16M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $235.23M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $138.60M | Mar 10, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.17M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $80.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $140.92M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $177.74M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $120.33M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $105.73M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $96.92M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $98.64M | Mar 10, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $92.25M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $56.39M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $18.86M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $60.43M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $91.17M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $44.43M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $138.31M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $39.96M | Mar 18, 2021 |
| FY2019 | Dec 31, 2017 | ($26.37M) | Mar 10, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($528.19M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($482.46M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($489.63M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($428.31M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($316.68M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($286.07M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($177.07M) | Mar 18, 2021 |
| FY2019 | Jan 1, 2019 | ($84.19M) | Mar 10, 2020 |
| FY2019 | Dec 31, 2018 | ($85.19M) | Mar 10, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $110.82M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $85.90M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $116.68M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $189.58M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $143.66M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $89.80M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $180.89M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $103.19M | Mar 10, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $22.22M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $2.48M | Mar 9, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (15) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | (38) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (15) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | (38) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 24.09M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 8.20M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 4.16M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | 3.70M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 60.90M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 52.69M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | 51.16M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 15.91M | Mar 10, 2020 |